were treated sequentially with addition of a LABA (salmeterol), addition of a long-acting anticholinergic agent (tiotropium; Spiriva), or a doubled IC dose. Each arm lasted 14 weeks. Both ...

Every medication, regardless of its intended use, comes with some risks. Unfortunately, they aren't always apparent right away. In some cases, doctors only learn about the risks of some medications ...

Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD). Design ...

Boehringer’s lung drug Spiriva, approved for chronic obstructive pulmonary disease (COPD) and asthma, generated net sales of 2.4 billion euros, down 11.4% compared with last year, which the ...

As the EU patent expires on its flagship respiratory diseases product, Spiriva, Boehringer Ingelheim is looking to newer diabetes and respiratory drugs under the leadership of a new CEO.